Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 12/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9247317 | 0.85 | HTR2A (0.35) | ALDH1A1TSHRHTR2AHRH1 | |
| SCHEMBL15223803 | 0.84 | USP2 (0.41) | — | |
| SCHEMBL20179472 | 0.83 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4AKDM4CKDM5A | |
| SCHEMBL19545894 | 0.83 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4AKDM4CKDM5A | |
| SCHEMBL10427910 | 0.81 | GPR84 (0.52) | — | |
| SCHEMBL17359140 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRKDM4AKDM4CKDM5A | |
| SCHEMBL5530871 | 0.79 | GPR84 (0.55) | — | |
| SCHEMBL3116423 | 0.79 | GPR84 (0.55) | — | |
| SCHEMBL308689 | 0.79 | GPR84 (0.55) | — | |
| SCHEMBL18221941 | 0.79 | GPR84 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115927424-A | Quorum-sensing escherichia coli self-cracking system and application thereof | 浙江工业大学 | 2023-04-07 | — | — | CN | claimed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250115656-A1 | Variant Chrmine Proteins Having Accelerated Kinetics and/or Red-Shifted Spectra | THE UNIVERSITY OF TOKYO (JP) | 2025-04-10 | — | — | US | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4469149-A2 | VARIANT CHRMINE PROTEINS HAVING ACCELERATED KINETICS AND/OR RED-SHIFTED SPECTRA | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240350422-A1 | FORMULATION PROCESS FOR CPMV NANOPARTICLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-10-24 | — | — | US | disclosed |
| WO-2023009458-A2 | FORMULATION PROCESS FOR CPMV NANOPARTICLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-115537372-A | Antigen presenting cell mimetic scaffolds and methods of making and using same | 哈佛学院院长等 | 2022-12-30 | — | — | CN | disclosed |
| CN-115404196-A | Antigen presenting cell mimetic scaffolds and methods of making and using same | 哈佛学院院长等 | 2022-11-29 | — | — | CN | disclosed |
| CN-115305229-A | Antigen presenting cell mimetic scaffolds and methods of making and using same | 哈佛学院院长等 | 2022-11-08 | — | — | CN | disclosed |
| CN-115137664-A | Cosmetic composition containing radix astragali peptide ripened product for improving skin activity | 株式会社现代百朗德 | 2022-10-04 | — | — | CN | disclosed |
| CN-114949240-A | IL-2 conjugates and methods of use thereof | 新索思股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220211881-A1 | COATED PLANT VIRUS IMAGING AGENTS | NATIONAL SCIENCE FOUNDATION | 2022-07-07 | — | — | US | disclosed |
| CN-109321447-B | Methods, systems and devices for detecting and identifying microorganisms in a microbial culture sample | 贝克顿·迪金森公司 | 2022-06-28 | — | — | CN | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-4321172-A | Organic polymers with acylurea repeating units having tertiary amino groups pendant therefrom and cathodic electrocoating of said polymers | DESOTO, INC. (US) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885TSHR 4869/4885KDM4A 2546/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885TSHR 4869/4885KDM4A 2546/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | ALDH1A1 3257/4885TSHR 3915/4885KDM4A 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.